Navigation Links
Anacor Files Registration Statement for Initial Public Offering
Date:8/31/2007

PALO ALTO, Calif., Aug. 31 /PRNewswire/ -- Anacor Pharmaceuticals announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares in the proposed offering are being sold by Anacor.

The underwriters of the offering will be Morgan Stanley & Co. Incorporated as sole book runner, Cowen and Company, LLC as co-lead, and Pacific Growth Equities, LLC and Needham & Company, LLC as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated by emailing prospectus@morganstanley.com, or by contacting the prospectus department at Morgan Stanley & Co. Incorporated, 180 Varick, New York, NY 10014, telephone (866) 718-1649.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. This registration statement is available on the Securities and Exchange Commission website at http://edgar.sec.gov. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. Anacor entered into a worldwide license, development and commercialization agreement for AN2690 with Schering-Plough for all indications including the treatment of onychomycosis. Pending discussions with the FDA, Anacor anticipates that Schering-Plough will initiate Phase 3 clinical trials for AN2690 in onychomycosis in 2008. In addition, Anacor has a portfolio of other topical product candidates in development for the treatment of psoriasis, gingivitis, acne, vaginal candidiasis and tinea pedis.


'/>"/>
SOURCE Anacor Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. PCR Polymerases Application Profiles
2. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
3. Obtaining a contour map from multifiles or 3D data in DataMax
4. Successful stabilization of gene expression profiles
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Third Wave files countersuit vs. Digene in patent case
7. TomoTherapy files registration statement for IPO
8. Merge files financial reports by market opening
9. The Why Files celebrates decade of science exploration
10. Third Wave files patent suits against Digene, Chiron and Bayer
11. New Web virus could lead to lost files, extortion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 25, 2017 , ... LABS, Inc. ... were added to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; ... LABS was only able to offer NAT screening for blood donors under an Investigational ...
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps ... and North America this May on the following dates: , ?    London, ... Taylor, Chairman of the Learning and Performance Institute will be the opening ...
(Date:4/26/2017)... April 26, 2017  Genisphere LLC, provider of ... signed a collaborative and sponsored research agreement with ... Muro . The overall goal of the partnership ... various 3DNA designs and formulations after in ... of the vasculature as well as inflammatory responses, ...
(Date:4/25/2017)... Oakland, California (PRWEB) , ... April 25, 2017 ... ... Artificial Intelligence (AI), leading supplier of Common Lisp (CL) development tools, and market ... 10.1 , which includes key performance enhancements now available within the most effective ...
Breaking Biology Technology:
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/16/2017)... 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... Used combined in one project, ... ...
(Date:3/9/2017)... March 9, 2017 4Dx has publicly released ... Imaging Workshop at the University of Pennsylvania. Founder and ... deliver the latest data to world leaders in lung ... together leaders at the forefront of the industry to ... "The quality of the imaging is ...
Breaking Biology News(10 mins):